Avivagen Inc. Logo

Avivagen Inc.

VIVXF

(2.2)
Stock Price

0,00 USD

-799.08% ROA

122.1% ROE

-0x PER

Market Cap.

10.608,10 USD

-78.15% DER

0% Yield

-645.91% NPM

Avivagen Inc. Stock Analysis

Avivagen Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Avivagen Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (84.14%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

With a remarkably low PBV ratio (-0.04x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a minimal amount of debt (-81%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

5 Net Profit Growth

The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors.

6 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

7 ROA

The stock's ROA (-1727.34%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Avivagen Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Avivagen Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Sell
4 Stoch RSI Hold

Avivagen Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Avivagen Inc. Revenue
Year Revenue Growth
2006 54.711
2007 359.051 84.76%
2008 412.249 12.9%
2009 1.183.516 65.17%
2010 184.536 -541.35%
2011 289.314 36.22%
2012 417.564 30.71%
2013 110.517 -277.83%
2014 295.671 62.62%
2015 163.966 -80.32%
2016 161.190 -1.72%
2017 255.660 36.95%
2018 1.072.572 76.16%
2019 977.451 -9.73%
2020 1.177.857 17.01%
2021 1.295.991 9.12%
2022 939.173 -37.99%
2023 162.100 -479.38%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Avivagen Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2006 395.186
2007 862.621 54.19%
2008 1.051.646 17.97%
2009 1.393.508 24.53%
2010 1.485.392 6.19%
2011 976.525 -52.11%
2012 850.858 -14.77%
2013 376.444 -126.03%
2014 587.383 35.91%
2015 551.173 -6.57%
2016 795.213 30.69%
2017 825.185 3.63%
2018 534.981 -54.25%
2019 640.622 16.49%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Avivagen Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 1.310.430 100%
2013 1.981.344 33.86%
2014 1.619.348 -22.35%
2015 1.467.069 -10.38%
2016 1.938.868 24.33%
2017 4.159.446 53.39%
2018 4.265.175 2.48%
2019 3.774.132 -13.01%
2020 4.328.194 12.8%
2021 4.688.629 7.69%
2022 1.896.923 -147.17%
2023 1.727.124 -9.83%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Avivagen Inc. EBITDA
Year EBITDA Growth
2006 -812.071
2007 -979.150 17.06%
2008 -1.237.749 20.89%
2009 -1.240.894 0.25%
2010 -2.542.339 51.19%
2011 -2.768.914 8.18%
2012 -1.856.253 -49.17%
2013 -2.251.633 17.56%
2014 -2.062.114 -9.19%
2015 -1.988.052 -3.73%
2016 -2.597.108 23.45%
2017 -4.833.925 46.27%
2018 -4.532.343 -6.65%
2019 -4.105.726 -10.39%
2020 -3.408.554 -20.45%
2021 -4.683.355 27.22%
2022 -846.031 -453.57%
2023 -1.640.792 48.44%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Avivagen Inc. Gross Profit
Year Gross Profit Growth
2006 54.711
2007 359.051 84.76%
2008 412.249 12.9%
2009 1.183.516 65.17%
2010 184.536 -541.35%
2011 257.186 28.25%
2012 305.035 15.69%
2013 106.155 -187.35%
2014 240.113 55.79%
2015 162.854 -47.44%
2016 158.746 -2.59%
2017 172.478 7.96%
2018 653.737 73.62%
2019 526.481 -24.17%
2020 470.980 -11.78%
2021 534.340 11.86%
2022 400.299 -33.49%
2023 95.168 -320.62%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Avivagen Inc. Net Profit
Year Net Profit Growth
2006 -812.516
2007 -1.038.067 21.73%
2008 -1.268.955 18.2%
2009 -1.344.601 5.63%
2010 -2.779.147 51.62%
2011 -3.509.866 20.82%
2012 -1.973.763 -77.83%
2013 -2.024.024 2.48%
2014 -2.080.388 2.71%
2015 -2.003.955 -3.81%
2016 -2.752.498 27.2%
2017 -5.135.661 46.4%
2018 -4.834.059 -6.24%
2019 -4.836.420 0.05%
2020 -4.751.287 -1.79%
2021 -6.394.159 25.69%
2022 -6.066.206 -5.41%
2023 -3.731.672 -62.56%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Avivagen Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 0
2007 -1 0%
2008 -1 0%
2009 -1 0%
2010 -1 0%
2011 -1 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Avivagen Inc. Free Cashflow
Year Free Cashflow Growth
2006 -695.673
2007 -1.257.348 44.67%
2008 -673.070 -86.81%
2009 -1.143.603 41.14%
2010 -2.213.070 48.33%
2011 -1.845.659 -19.91%
2012 -2.086.794 11.56%
2013 -2.653.067 21.34%
2014 -1.768.258 -50.04%
2015 -1.641.835 -7.7%
2016 -2.184.549 24.84%
2017 -4.772.743 54.23%
2018 -3.878.936 -23.04%
2019 -3.631.296 -6.82%
2020 -3.379.983 -7.44%
2021 -4.607.752 26.65%
2022 -3.116.538 -47.85%
2023 71.514 4457.94%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Avivagen Inc. Operating Cashflow
Year Operating Cashflow Growth
2006 -687.411
2007 -950.279 27.66%
2008 -639.492 -48.6%
2009 -1.138.795 43.84%
2010 -1.931.235 41.03%
2011 -1.829.233 -5.58%
2012 -2.058.309 11.13%
2013 -2.653.067 22.42%
2014 -1.768.258 -50.04%
2015 -1.641.835 -7.7%
2016 -2.184.549 24.84%
2017 -4.772.743 54.23%
2018 -3.809.397 -25.29%
2019 -3.522.092 -8.16%
2020 -3.335.688 -5.59%
2021 -4.599.045 27.47%
2022 -3.116.538 -47.57%
2023 71.514 4457.94%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Avivagen Inc. Capital Expenditure
Year Capital Expenditure Growth
2006 8.262
2007 307.069 97.31%
2008 33.578 -814.49%
2009 4.808 -598.38%
2010 281.835 98.29%
2011 16.426 -1615.79%
2012 28.485 42.33%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 69.539 100%
2019 109.204 36.32%
2020 44.295 -146.54%
2021 8.707 -408.73%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Avivagen Inc. Equity
Year Equity Growth
2006 -25.811
2007 -19.226 -34.25%
2008 -1.147.632 98.32%
2009 -1.102.298 -4.11%
2010 -2.463.208 55.25%
2011 -4.321.468 43%
2012 -4.220.277 -2.4%
2013 -1.929.601 -118.71%
2014 -2.392.033 19.33%
2015 -2.825.064 15.33%
2016 400.528 805.33%
2017 168.786 -137.3%
2018 93.779 -79.98%
2019 -3.256.215 102.88%
2020 -4.767.610 31.7%
2021 -3.952.665 -20.62%
2022 -5.983.919 33.95%
2023 -9.265.415 35.42%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Avivagen Inc. Assets
Year Assets Growth
2006 207.007
2007 749.568 72.38%
2008 613.742 -22.13%
2009 1.487.798 58.75%
2010 1.263.670 -17.74%
2011 360.842 -250.2%
2012 395.092 8.67%
2013 1.401.876 71.82%
2014 868.647 -61.39%
2015 692.710 -25.4%
2016 5.196.195 86.67%
2017 1.849.687 -180.92%
2018 3.109.230 40.51%
2019 1.887.679 -64.71%
2020 2.176.142 13.26%
2021 3.477.774 37.43%
2022 1.365.394 -154.71%
2023 272.532 -401%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Avivagen Inc. Liabilities
Year Liabilities Growth
2006 232.818
2007 768.794 69.72%
2008 1.761.374 56.35%
2009 2.590.096 32%
2010 3.726.878 30.5%
2011 4.682.310 20.41%
2012 4.615.369 -1.45%
2013 3.331.477 -38.54%
2014 3.260.680 -2.17%
2015 3.517.774 7.31%
2016 4.795.667 26.65%
2017 1.680.901 -185.3%
2018 3.015.451 44.26%
2019 5.143.894 41.38%
2020 6.943.752 25.92%
2021 7.430.439 6.55%
2022 7.349.313 -1.1%
2023 9.537.947 22.95%

Avivagen Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.03
Price to Earning Ratio
-0x
Price To Sales Ratio
0.09x
POCF Ratio
0.08
PFCF Ratio
0.08
Price to Book Ratio
-0
EV to Sales
61.2
EV Over EBITDA
-6.14
EV to Operating CashFlow
56.11
EV to FreeCashFlow
56.11
Earnings Yield
-205.28
FreeCashFlow Yield
12.15
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.27
Graham NetNet
-0.12

Income Statement Metrics

Net Income per Share
-0.03
Income Quality
-0.06
ROE
0.25
Return On Assets
-4.44
Return On Capital Employed
1.27
Net Income per EBT
1
EBT Per Ebit
6.5
Ebit per Revenue
-0.99
Effective Tax Rate
-0.29

Margins

Sales, General, & Administrative to Revenue
10.41
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.21
Gross Profit Margin
0.43
Operating Profit Margin
-0.99
Pretax Profit Margin
-6.46
Net Profit Margin
-6.46

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.71
Return on Tangible Assets
-7.99
Days Sales Outstanding
147.12
Days Payables Outstanding
4142.38
Days of Inventory on Hand
386.43
Receivables Turnover
2.48
Payables Turnover
0.09
Inventory Turnover
0.94
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,12
Tangible Book Value per Share
-0.12
Shareholders Equity per Share
-0.12
Interest Debt per Share
0.11
Debt to Equity
-0.78
Debt to Assets
26.57
Net Debt to EBITDA
-6.14
Current Ratio
0.03
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-8163181
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
80362
Debt to Market Cap
682.57

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Avivagen Inc. Dividends
Year Dividends Growth

Avivagen Inc. Profile

About Avivagen Inc.

Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.

CEO
Mr. G. F. Kym Anthony
Employee
13
Address
100 Sussex Drive
Ottawa, K1A 0R6

Avivagen Inc. Executives & BODs

Avivagen Inc. Executives & BODs
# Name Age
1 Ms. Tracy Gillett BVSC
Director of Companion Animal & Marketing Manager
70
2 Dr. James Nickerson Ph.D.
President and Executive Vice President of Business Development & Product Innovation
70
3 Mr. G. F. Kym Anthony
Chief Executive Officer & Vice Chairman
70
4 Dr. Graham Burton Ph.D.
Co-Founder, Chief Scientific Officer & Director
70
5 Mr. Ira Levy
Interim Chief Financial Officer
70
6 Mr. Drew Basek
Director of Investor Relations
70

Avivagen Inc. Competitors